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At the time of organ offer for transplantation, donor-related risks such as disease trans-
mission and graft failure are weighed against the patient’s risk of remaining on the 
waiting list. The patient’s commonly inactive role in decision making and the timing 
and extent of donor-specific risk information have been discussed in the medical litera-
ture. This is the first study revealing the opinion of liver patients on these issues. Forty 
patients listed for liver transplantation and 179 transplanted liver patients participated 
in an anonymous questionnaire-based survey. The majority of patients wanted to be 
informed about donor-related risks (59.8%-74.8%). The preferred timing for being in-
formed about donor-related risks was the time of the organ offer for 53.3% of the pa-
tients. Among these patients, 79.8% wished to be involved in making the decision to 
accept or not to accept a liver for transplantation, 10.6% wished to make the final deci-
sion alone, and only 9.6% did not want to be involved in the decision-making process. 
Implementing this knowledge through the standardization of the content, the manner 
of transfer, and the amount of information that we provide to our patients will improve 
opportunities for shared decision making at different time points during the transplant 
allocation process. This will enable us to provide the same opportunities and care to 
every patient on the waiting list.




Liver transplant waiting lists increase more rapidly than the supply of donor organs, 
and this leaves many patients stranded and without access to what is often a lifesaving 
therapy. Efforts to increase the donor pool include the acceptance of more donors at 
the expense of diminished organ quality [ie, extended criteria donors (ECD)]. An ECD 
implies a higher donor-related risk in comparison with a standard criteria donor (SCD). 
This risk may manifest as an increased incidence of poor allograft function, allograft 
failure, or transmission of a donor-derived disease.1 
To what extent such donor-related risks are discussed with the liver transplant candi-
date (informed consent) varies between countries and hospitals; whether or not the 
transplant candidate is involved in the decision-making process (shared decision mak-
ing) at the time of donor offer also varies.2-4 
In the United States, since the 2007 implementation of the guidelines from the Centers 
for Medicare and Medicaid Services (US Department of Health and Human Services), 
consent forms have been required for various stages of the transplant process, which 
starts with the initial evaluation and ends with the surgery. However, consent for ECD 
liver transplantation is not a requirement of the Centers for Medicare and Medicaid 
Services; it is offered at the discretion of the provider.3 A recent study by Bruzzone et 
al.2 has provided insight in the European implementation of informed consent for ECD 
liver donation: the majority of transplant centers inform transplant candidates about 
the ECD status of the donor, but great variations were observed in the timing of inform-
ing (before listing and/or at the time of organ offer), in the topics discussed, and in 
whether a special consent form was signed.
Standardization for the timing and content of the informed consent and for the trans-
plant patient’s role in the decision-making process is currently lacking, although both 
topics are receiving increasing attention in medical literature.5-9 Informed consent is the 
term used for a patient’s voluntary authorization, with full comprehension of the risks 
involved, for medical and surgical treatment.10 Shared decision making is the process by 
which a health care provider communicates personalized information about options, 
outcomes, probabilities, and the uncertainties of the available options and a patient 
communicates values and the relative importance of benefits and harms.11 For both 
informed consent and shared decision making, informing patients of all risks involved 
with a certain treatment is essential. Health researchers and policy-makers increasingly 
urge both patient and clinician engagement in shared decision making to facilitate the 
greater involvement of patients in their personal healthcare management.12 Paternal-
istic health care has fallen out of favour and has been replaced by the patient-centered 
model, which emphasizes patient autonomy, informed consent and empowerment.13 
Although shared decision making has been examined and implemented in numerous 
clinical settings,14,15 it has received little attention in solid organ transplantation, es-
pecially in the field of (deceased donor) liver transplantation.8,12 In a transplant set-
ting, decisions often have to be made quickly, and the risks and benefits are difficult 
to explain fully at the time of an organ offer; this complicates informed consent and 
particularly patient involvement in shared decision making. Moreover, medical decision 
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making for liver transplantation raises additional challenges for shared decision making 
because liver transplant patients have no effective medical alternatives to transplanta-
tion such as dialysis in renal patients.12 
Various ideas about the patient’s role in decision-making and the timing and extend 
of informed consent have been proposed in medical literature.6,8,16 However, there is a 
more fundamental question to be answered first: what do patients really want? There 
is very limited information on (1) the donor-related risk information that patients want 
to receive, (2) the preferred timing of ECD informed consent, (3) whether potential 
transplant candidates want to be involved in decision-making at the time of organ al-
location, and (4) how much risk they are willing to accept. We, therefore, performed an 
anonymous questionnaire-based survey among patients listed for transplantation and 
liver transplant patients that addressed these questions. 
PATIENTS AND METHODS 
Participants and study design
All liver transplant recipients who underwent transplantation at an adult age at the 
University Medical Center in Groningen between 2000 and 2010, and who were still 
receiving posttransplant care at our center were invited to participate. In addition, 
adult patients that were actively listed for transplantation on February 1, 2013, were 
invited to participate. All eligible posttransplant and pretransplant patients received 
an information letter and a self-administered questionnaire by mail. Questionnaires 
were coded, and confidentiality was guaranteed. After 4 weeks, a reminder was sent 
to non-responders, and they were allowed another 4 weeks for completion. The study 
met the criteria for an exemption from approval (approval letter METc2012.306). The 
questionnaire was composed for the purpose of the study under guidance of an expe-
rienced health psychology researcher (A.V.R.) because no standard questionnaire was 
available for this topic. Internal validation questions were added to assess patients’ 
understanding of the questionnaire, and the demonstrated conformity of 90% to 96%. 
The questionnaire was divided into two parts: (1) donor organ information, which con-
tained 18 questions, and (2) general information, which contained 6 questions. All of 
the questions are addressed in the assessment section.
Assessment
All liver patients were approached by mail and asked to complete a 20 to 30 minute 
questionnaire. Patients were first reminded of the distinction between SCD livers and 
donor livers with an increased risk of complications after transplantation (so-called ECD 
livers). The difference between the general risk of a transplant procedure and (specific) 
donor-related risks was explained. An age >60 years, steatosis, and donation after car-
diac death (DCD) were described as risk factors for liver failure and bile duct complica-
tions. Also, the potential risk of a transfer of a malignancy or an infectious disease from 
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the donor to the recipient was explained. After this introduction, patients were asked 
4 personal questions concerning their time on the waiting list, previous experience 
with liver transplantation, and experience with complications after liver transplantation 
(questions 1-4).
Patients’ acceptable risk of disease transmission (questions 5-8).
Next, patients were informed that the risk of a malignancy or infectious disease being 
transferred from a SCD livers is generally kept at less than 1%, and this leads to the dis-
carding of livers that are otherwise suitable for transplantation. Patients then were asked 
to indicate on a visual proportion scale (1-50%) the risk of disease transmission that they 
considered high, and they were then asked to indicate the risk of disease transmission 
that they were willing to accept. The latter 2 questions were repeated (on the following 
page) after the patients were informed about the 15% mortality rate on the waiting list. 
Informing patients about donor-related risks (questions 9-12)
In the subsequent questions, patients were asked whether they wished to be informed 
when a donor liver was offered with (1) an increased risk of transferring an infectious 
disease such as hepatitis or human immunodeficiency virus (HIV), (2) an increased risk 
of transferring a malignant disease (tumor), (3) an increased risk of bile duct strictures, 
or (4) an increased risk of early graft failure. Early graft failure was explained as requir-
ing re-transplantation within 2 weeks after transplantation. 
Timing of donor-specific informed consent (questions 13 and 14).
Next, it was explained that patients are informed (in general terms) about donor-relat-
ed risks before waiting-list registration. It is currently not common practice to inform 
patients about specific donor-related risks at the time of donor offer. First, patients 
were asked to agree or disagree on a 5-point Likert scale (strongly disagree to strong-
ly agree) with 4 statements through motives for wanting or not wanting information 
about donor-related risks were explored:
13a.  It would cause distress (I would worry) if I received information about donor-
related risks at the time of donor offer.
13b.  I would like to receive information about donor-related risks at the time of donor 
offer, because it will allow me to be mentally prepared.
13c.  I prefer not to receive information about donor-related risks at the time of donor 
offer, because I will already be overwhelmed.
13d. I would like to receive information about donor-related risks at the time of donor 
offer, since it will allow me to decide whether I do or do not want to receive that 
donor liver. 
Subsequently, patients were asked whether they wished to be informed about donor-
related risks of the liver offered to them for transplantation, with the following options 
for answers: 
• No, I do not want to be informed about the donor-related risks.
• I want to be informed at the time of donor offer, even when this is at 3 AM.
• I want to be informed afterwards, when I have recovered from the transplant surgery. 
84
CHAPTER 5
The patient’s role in the decision process (questions 15 and 16)
The patients who wished to be informed at the time of the donor offer, were asked 
what they planned to do with the acquired information: 
• I just want to know, the decision on whether or not to accept the liver should be 
made by my physicians.
• I would like to make the decision together with my physician; we should decide to-
gether on whether or not to accept the liver.
• I would like to make the final decision alone (by myself).
Next, it was explained that in some countries, listed patients are allowed to exclude 
certain groups of livers (ECD livers) from being offered to them for transplantation, 
such as donation after cardiac death livers, livers from older donors, and livers from 
donors with an increased risk of infectious disease transmission. They were told that 
this would decrease the risk of complications after transplantation, but it would also 
increase the waiting time for a donor liver and thereby increase the mortality risk while 
on the waiting list. Patients were asked if they wanted to be able to exclude certain 
groups of donor livers before they were listed for transplantation. 
Presented cases (questions 17 and 18)
Finally, two cases were presented to the patients: one concerning an 18-year old donor 
acquainted with intravenous drug use and the other concerning a healthy 81-year old 
donor (Table 1). First, patients were asked to assess the expected risk of infectious 
disease transmission and early graft failure, respectively, in those 2 cases. Next, the 
patients were asked whether they would accept these livers for transplantation if (1) 
their personal medical situation were stable and (2) their liver disease was progres-
sively severe and the situation were, therefore, unstable.
Through 6 additional questions, information was obtained about patient age, sex, 
country of origin, civil status, education, and employment status. Data regarding the 
primary liver disease etiology and the time on the waiting list were extracted from 
medical databases.
Statistical analysis
Data were expressed as means and standard deviations, medians, or percentage of par-
ticipants with specific responses. Categorical variables were compared with the Pear-
son Chi-square test or Fisher’s Exact test as appropriate. Continuous variables were 
compared with the Student t test. Repeated measurements of ordinal variables within 
one group were compared using the Wilcoxon signed-rank test. The level of signifi-
cance was set at a P value of 0.05. Statistical analyses were performed using SPSS 16.0 
for Windows (SPSS, Inc., Chicago, IL).
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Table 1. Two cases and situations: Would you accept this liver?
Acceptable?
Yes No Uncertain
Case A.  A young man (18 years old) died of an acute 
stroke (brain death). He was in good health, and his 
blood liver tests were normal. There is no evidence of 
a (endured) virus infection like Hepatitis B or C virus or 
HIV. However, the donor was acquainted with intravenous 
heroin use. 
Situation 1: You have been listed for transplantation for 
8 months, and your condition is deteriorating: you are 
admitted to the hospital with significant jaundice, ascites 
and fatigue. There are concerns about whether there will 
be a liver available for transplantation in time.
74.3% 2.8% 22.9%
Case B. The donor profile is the same as that for case A. 
Situation 2. You have been listed for transplantation for 
8 months, and your condition is fairly stable. You work 
part-time (half days) because of your liver disease, and 
you suffer mild jaundice. Arguably, you have some time to 
wait for a suitable organ offer.
40.7% 16.8% 42.5%
Case C. An 81-year-old woman died of an acute stroke. 
She lived more or less independently and relied on her 
neighbours only for help with groceries. She was healthy 
for her whole life. Her blood liver tests were normal.
Situation 1. You have been listed for transplantation for 
8 months, and your condition is deteriorating: you are 
admitted to the hospital with significant jaundice, ascites 
and fatigue. There are concerns about whether there will 
be a liver available for transplantation in time.
73.1% 3.3% 23.6%
Case D. The donor profile is the same as that for case C.
Situation 2: You have been listed for transplantation for 
8 months, and your condition is fairly stable. You work 
part-time (half days) because of your liver disease and 
you suffer mild jaundice. Arguably, you have some time to 






Patients on the waiting list with an inactive status (n = 18) and patients who were <18 
years old (n = 15) were excluded. In all, 243 transplanted patients and 66 patients on 
the waiting list were invited to participate. The overall response was 70.9% (n = 219); 
this included 60.6% (n = 40) of the approached waiting list patients and 73.7% (n = 179) 
of the transplant patients.
The study population was predominantly middle-aged, male, Dutch, married, and edu-
cated at an intermediate level (Table 2). The most common indications for transplanta-
tion were non-cholestatic cirrhosis (34.7%), cholestatic cirrhosis (33.3%), and metabol-
ic disease (10.5%). The time since (last) liver transplantation was 6.4 ± 3.1 years (mean 
and standard deviation) for transplant patients and 9.4 ± 4.2 years for patients on the 
waiting list who had been transplanted before (n = 8; 20% of all participating listed pa-
tients). Ninety-nine of all transplant patients, 55.3% had developed 1 or more compli-
cations after transplantation, with biliary complications being the most common (n = 55 
or 30.2%). The average time on the waiting list was 34.9 months (median = 26 months, 
interquartile range = 6-49 months) for the waiting-list patients. Nonresponders did not 
differ significantly from responders with respect to sex, liver disease before transplan-
tation, or time since last transplantation. However, nonresponders were significantly 
younger (46.7 ± 16.6 versus 54.5 ± 13.1, P <0.001). During the study period, 2 nonre-
sponders died, and 1 was admitted to the hospital.
Patient’s view on acceptable risk of disease transmission
In general practice, the risk of disease transmission during organ transplantation is kept 
at less than 1% (no additional risk). Patients reported a significantly higher willingness 
to accept an increased risk of disease transmission after they had received informa-
tion about the current 15% waiting-list mortality rate (Figure 1). The risk of disease 
transmission that patients were willing to accept was 7% ± 1% (mean and standard 
error), which increased to 12% ± 1% after they had received information about the cur-
rent waiting-list mortality (P <0.001). No significant differences were found between 
subgroups based on patient status (transplant/waiting list), age, sex, level of education 
(low/intermediate/high), country of origin (Netherlands/other), or civil status (living 
alone/living with partner).
Informing about different types of donor-related risks
The vast majority wished to be informed when donor-related risks increased. When 
there was an increased risk of the transmission of an infectious disease or a malignant 
tumor, 73.5% and 74.8% of respondents, respectively, wished to be informed. In the 
case of an increased risk of bile duct strictures, 59.8% of respondents wished to be in-
formed. When an increased risk of early graft failure was present, 70.1% of the patients 
wished to be informed (Table 3). Experience with bile duct complications or early graft 
failure after liver transplantation (the patient or an acquaintance) was not associated 
with an increased wish to be informed about an increased risk of bile duct strictures 
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Sex:  female {n/N(%)}
Country of origin
     Netherlands
     Other
Civil status
     Married
     De facto union
     Partner, not living together
     No partner
     Divorced
     Widow
Highest education achieved
     Lower vocational education or primary school
     Intermediate vocational education
     Higher vocational education or university
Occupation
     Full-time/part-time job
     Retired
     Partial or complete incapacity to work
     Other†
Liver disease (before transplantation)
     Acute hepatic failure
     Non-cholestatic cirrhosis
     Cholestatic cirrhosis
     Metabolic disease
     Hepatocellular carcinoma
     Congenital pediatric liver disease
     Miscellaneous
Liver transplantation in the past
Time since (last) liver transplantation, years
















































































9.4 ± 4.2 (n=8)
34.9 ± 43.2
The data are presented as n/total n (%).
*The data are presented as means and standard deviations.
†Student, volunteer, job seeker, etc.
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or early graft failure, respectively. No significant differences were found between sub-
groups based on age, sex, level of education (low/intermediate/high), country of origin 
(Netherlands/other) or civil status (living alone/living with partner). However, in com-
parison with transplant patients, significantly more waiting-list patients wished to be 
informed about donor-related risks (Table 3). 
Preferred time for providing donor-related risk information
Approximately half of the patients (53.3%) wished to be informed at the time of the 
organ offer, 18.8% of the patients preferred to be informed after the transplant pro-
cedure, and 27.7% did not wish to be informed at all. Significantly more waiting-list 
patients wished to be informed at the time of organ offer (71.1%) in comparison with 
transplant patients (49.4%, P = 0.02; Figure 2). Younger patients (<40 years) wished 
to be informed at the time of the organ offer more often (70.3%), than older patients 
(55.6% for patients 41-60 years old and 44.0% for patients >60 years old). More pa-
 
         Before   After Before After
Transplant 
patients






















Moderately higher risk 
(1-10%) 
No additional risk (max 1%)
Figure 1. Risk of disease transmission that is viewed as acceptable: acceptable risk of disease 
transmission before and after the receipt of information about the 15% waiting-list mortality rate. 
No differences were observed between transplant patients and patients on the waiting list for liver 
transplantation
Table 3. Number of patients wishing to be informed about donor-related risks 






Increased risk of infectious disease 
transmission
Increased risk of malignant tumor 
transmission
Increased risk of developing bile duct 
strictures

















NOTE: the data are presented as numbers and percentages.
* Re-transplantation was required within 2 weeks after transplantation
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tients with a lower level of education preferred not to be informed at all (43.8%) in 
comparison  with intermediately educated patients (25.5%) or more highly educated 
patients (16.9%, P = 0.03). No significant differences were found between subgroups 
based on sex, country of origin (Netherlands/other), or civil status (living alone/living 
with partner). In comparison with waiting-list patients, significantly more transplant 
patients indicated that they would feel worried if donor-related risk information were 
provided at the time of organ offer (59.5% versus 39.5%, P = 0.048) and that they would 
feel overwhelmed (39.2% versus 18.4%, P = 0.047).
The patient’s role in the decision process
All respondents who wished to be informed about donor-related risk at the time of 
organ offer were asked whether they wished to be actively involved in the decision-
making process for accepting or declining the liver for transplantation. Overall, 79.8% 
of the respondents preferred shared decision-making, 10.6% wished to make the final 
decision alone, and only 9.6% did not want to be involved in the decision-making pro-
cess. No significant differences were found between subgroups based on age, sex, level 
of education (low/intermediate/high), country of origin (Netherlands/other), or civil 
status (living alone/living with partner). As presented in Figure 2, significantly more 
 
Patients on the waiting list
When would you like to be informed:
Transplanted patients: 
When would you like to be informed:
What would you do with this information?
What would you do with this information?
Final decision alone
Shared decision-making
Not involved in decision-making
Wish not to be informed
After recovery from the transplant surgery
At the time of donor offer
Final decision alone
Shared decision-making
Not involved in decision-making
100%
Figure 2. Timing and results of providing donor-related risk information. The majority of the patients 
wanted to be informed about donor-related risks at the time of organ offer (pie charts on left) and 
wished to be involved in the decision-making process (bars graphs on right).
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waiting-list patients wished to be involved in shared decision making (100%), when 
compared to transplant patients (73.8%, P = 0.02). 
Patients were asked whether they want to be able to exclude certain groups of donor 
livers before they were listed for transplantation. Only 21.6% of the transplant patients 
and 31.6% of the waiting-list patients wished to be able to exclude certain groups of 
donor livers, before they were listed for transplantation. No differences were found 
between the aforementioned subgroups.
Presented cases 
Finally, 2 potential donor cases were presented: a healthy 18-year-old previous heroin 
user who had tested negative for HIV and a healthy 81-year-old donor. Only 19.4% of 
all patients judged the risk of disease transmission associated with accepting the liver 
from the 18-year-old donor to be high. Similarly, only 16.5% of the patients judged 
the risk of potential nonfunction for the 81-year-old liver to be high. If the respon-
dent’s own condition were deteriorating, no less than 74.3% would accept the liver 
from the 18-year-old previous heroin user, and 73.1% would accept the liver from the 
healthy 81-year-old donor. If the respondent’s own condition were moderately stable, 
still 40.7% would accept the 18-year-old liver, and 39.2% would accept the 81-year-old 
liver (Table 1).
In the case of the healthy 18-year-old previous heroin user, no significant differences 
were found between subgroups based on patient status (waiting list/transplant), age, 
level of education (low/intermediate/high), country of origin (Netherlands/other) or 
civil status (living alone/living with partner). However, significantly more male respon-
dents were willing to accept this 18-year-old liver in comparison with female respon-
dents: 50.4% versus 27.5% (P <0.001) if the respondent’s condition were moderately 
stable and 80.5% versus 65.9% (P = 0.05) if the respondent’s condition were deteriorat-
ing. In the case of the healthy 81-year-old donor, no significant differences were found 
between the aforementioned subgroups. 
DISCUSSION
Various ideas about the patient’s role in decision-making and the timing and extent of 
informed consent in transplantation have been proposed and discussed in literature by 
medical professionals.5-9,16 This is the first study revealing the opinions of liver patients 
on these issues. The 4 main findings are as follows: (1) most liver patients want to be 
informed about donor-related risks, (2) half of the liver patients want to be informed at 
the time of organ offer, (3) the majority of these patients wish to participate in making 
decision to accept or decline a potential donor liver, and (4) liver patients are willing to 
accept a relatively high risk of disease transmission and graft failure in comparison with 
the risk commonly accepted by physicians.
The vast majority of patients (59.8%-74.8%) want to be informed when the donor-re-
lated risk of infectious disease, a malignant tumor, bile duct strictures, or early graft 
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failure is increased. The need for a full, clear, and frank explanation about general 
and donor-specific risks of transplantation is supported in the literature.7,9 Moreover, 
better-informed patients may establish more realistic expectations, which in turn have 
been shown to improve postsurgical health outcomes and decrease legal claims.10,17 
This finding also supports the call for the standardization of informed consent before 
placement on the waiting list, which would promote the autonomy of recipients by 
helping to ensure that they are informed of all relevant donor risk factors.6
Interestingly, for more than 50% of the patients, the preferred timing of donor-related 
risk information is at the time of organ offer. Additionally, more than 90% of those 
patients want to be involved in making the decision to accept or decline a potential 
donor liver (shared decision making). This confronts medical teams with a dilemma: 
on one hand, the principles of patient autonomy and dignity require nothing less than 
complete disclosure, especially when potentially risky therapies are being offered,16 but 
on the other hand, the disclosure of donor-specific risks requires extra time precisely 
when time is at a premium (during organ offer), and this could, therefore, prevent the 
optimal use of the organ supply.6
A suggested alternative to informed consent and shared decision making at the time 
of organ offer is to give patients the opportunity to accept or decline ECD organs as a 
group before transplantation.6 However, a classification of organs into 2 groups might 
be inaccurate, because some of the standard organs would not be acceptable for cer-
tain recipients and not all ECD organs are of equal quality and risk.8 It has, therefore, 
been suggested that ECD organs be classified in several groups, but it is still question-
able whether the patient can understand the impact of these risks and make a good 
decision, especially because the patients’ own medical condition is a dynamic process 
that will change his or her willingness to accept ECD livers, as shown in this study. Only 
a quarter of the patients in this study wished to be able to exclude certain groups of 
donor livers before they were listed for transplantation.
It is recognized that shared decision making may not suit all types of patients. Studies of 
shared decision making have found that patients with more serious or life-threatening 
illnesses and those for whom there are no alternative treatments do not wish to partici-
pate in the decision-making process.18 In contrast to renal patients, patients with end-
stage liver disease have no effective medical alternatives to transplantation such as di-
alysis. Interestingly, this study showed that the majority of the liver transplant patients 
actually did want to be involved in shared decision making at the time of organ offer.
This study also showed that patients are willing to accept a relatively high risk of dis-
ease transmission and potential graft failure, especially when their clinical situation 
is deteriorating. Previous studies have shown a similar high willingness of patients to 
accept donor-related risks such as ECD donor livers or donor kidneys at risk for viral 
infections.19,20 Interestingly, we noticed that informing the patients of the 15% waiting- 
list mortality rate significantly increased their willingness to accept more donor-related 
risk. This suggests that providing information affects the decision-making process. Pro-
viding standardized information on the risks and benefits of the different types of ECD 
donor transplantation at the time of waiting-list registration, potentially in combination 
with comprehension assessment tools and e-health educational tools, might enable 
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liver patients to participate in shared decision making at the time of organ offer. Deci-
sion aids have been demonstrated to affect long-term behavior and appear to promote 
informed decision-making.21
A potential bias could reside in the fact that we do not know whether the nonresponders 
to this questionnaire would have given the same answers to the questions in comparison 
with the responders. We did, however, compare responder and nonresponder charac-
teristics, and we found no significant differences with respect to sex, liver disease, or 
time since transplantation. On the other hand, non-responders were approximately 8 
years younger. During the study period, 2 non-responders died, and 1 was admitted to 
the hospital.
This study is clinically relevant to anyone who is involved in transplantation. Decisions 
concerning the patient’s role in decision making and the timing and extent of informed 
consent in transplantation need to be made by every transplant center. Both the phy-
sician’s opinion and the patient’s opinion on these issues should be taken into con-
sideration. Standardization of both the information about the different donor types 
provided before patient listing and shared decision-making at the time of organ offer 
is important for providing the same opportunities and care to every patient. We are 
aware that the results of the current study only represent the opinion of liver patients 
in the Netherlands. This study was undertaken at a transplant center in the north of 
the Netherlands, an area that is known to be more culturally homogeneous than trans-
plant centers in the south of the Netherlands. The opinion of patients elsewhere in the 
world could be different. We hope that this study stimulates other transplant centers 
to perform a similar survey to reveal the local need for information and involvement of 
patients in the decision-making process surrounding liver transplantation.
In the case of deceased donor liver transplantation, decisions often have to be made 
quickly, and the risks and benefits are difficult to explain fully at the time of an organ 
offer. The involvement in shared decision making should be consistent with patient 
preferences; the process of involvement may be as important as who eventually makes 
the decision.11,22 On the basis of the results of this study, we suggest that information 
on risks related to SCD and ECD transplantation be provided in detail to all patients 
listed for transplantation. Moreover, patients who want to be informed and involved 
in shared decision making at the time of the organ offer should be identified at the 
time of listing for transplantation. Accordingly, these patients should receive additional 
information and potentially decision aids to allow shared decision making at the time 
of the organ offer.
In conclusion, the questionnaire presented in this paper provides unique information 
on the opinion of liver patients on donor-related risks. The majority of respondents 
wished to be informed about donor-related risks and wanted to be involved with 
shared decision making at the time of organ offer. Implementing this knowledge and 
standardizing the content, the manner of transfer, and the amount of information that 
we provide to our patients at different time points during the transplant allocation pro-
cess will be important for providing the same opportunities and care to every patient 
on the waiting list.
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